Cogstate is pleased to announce the appointment of Ms Kim Wenn as an Independent Non-Executive Director, effective immediately. Kim brings extensive technology experience and strong commercial expertise to the Board of Cogstate, with over 30 years experience in innovation roles.
Cogstate Receives Digital Biomarker Award from ADDF to Develop Mobile App for Early Detection of Memory Impairment
Cogstate today announced an award from the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) initiative, which is a partnership of funders seeking to develop novel biomarkers for the early detection of Alzheimer’s disease and related dementias. The up to $1.3 million award to Cogstate will be focused on the development of a technology-based approach for early detection of memory impairment and decline.
Eisai Co., Ltd (Tokyo) today announced the launch of “NouKNOW”, a digital tool for self-assessment of brain health based upon technology created by Cogstate. The Japanese product launch will occur on 31 March 2020 and will initially target municipalities providing health services to local residents and corporations providing health checks for employees.
Cogstate announced today that Ken Billard has joined the company in the role of Chief Commercial Officer. Ken brings proven expertise in sales leadership and strategic partnering to Cogstate, where he will oversee the global sales organization to develop and execute strategies focused on expanding the adoption of Cogstate solutions in pharmaceutical clinical trials.
Cogstate today announced the appointment of Eric Siemers, M.D., as Distinguished Medical Adviser. Dr. Siemers will provide expert advice for Cogstate’s pharmaceutical customers with regard to the design of clinical trials of neurodegenerative diseases.
Cogstate Strengthens Global Clinical Science Expertise with the Appointment of Senior Vice President, Dr. Chris Edgar
Cogstate today announced the addition of Dr. Chris Edgar, Senior Vice President, Clinical Science to its global scientific leadership team. Dr. Edgar joins the Cogstate team in Europe as an experienced leader in cognitive assessment and clinical endpoint strategy.
Cogstate today announced it has been chosen as the preferred provider to Eli Lilly and Company to support their Alzheimer’s disease platform with solutions to ensure high-quality neuropsychological outcome measures in clinical trials.
Cogstate announced today that Richard Gleeson has joined the senior leadership team as Chief Technology Officer, strengthening the company’s ability to deliver transformative innovations to optimize the measurement of cognition in clinical trials and healthcare.
Cogstate is pleased to announce the appointment of Jane McAloon as an Independent Non-Executive Director and Chair of the Audit & Compliance Committee of Cogstate Ltd.
Cogstate is pleased to announce the appointment of Dr. Richard Mohs as a non-executive director.